Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Boehringer Ingelheim
Johnson and Johnson
Merck
McKesson

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR NERLYNX


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Nerlynx

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00300781 ↗ Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer Completed Puma Biotechnology, Inc. Phase 2 2006-08-04 The purpose of this study is to learn whether neratinib is safe and effective in treating women with advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer.
NCT00706030 ↗ Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer Completed Puma Biotechnology, Inc. Phase 1/Phase 2 2008-04-29 The purpose of this study is to identify the highest tolerable dose of neratinib (HKI-272) in combination with vinorelbine and to assess the safety of the combination of the two drugs as well as to obtain preliminary information on whether the combination of the two drugs has any effect on solid tumors. The study will be conducted in two parts. In the first part, testing will be done on up to 12 subjects to determine the highest tolerable dose of HKI-272 and vinorelbine in patients with advanced solid tumors. In the second part of the study, approximately 60 additional subjects with metastatic ErbB-2-positive breast cancer, with no prior exposure to lapatinib, are planned to be added to better define the tolerability and preliminary activity of HKI-272 in combination with vinorelbine. Up to 20 additional subjects with ErbB-2-positive breast cancer with prior lapatinib exposure are also planned to be enrolled in part 2 for exploratory analyses.
NCT00878709 ↗ Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer Completed Puma Biotechnology, Inc. Phase 3 2009-07-09 The purpose of this study is to investigate whether neratinib can further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after adjuvant treatment with trastuzumab.
NCT00958724 ↗ Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors Completed Puma Biotechnology, Inc. Phase 1 2009-07-01 The purposes of this study are to evaluate the safety and tolerability of neratinib in combination with vinorelbine at the maximum tolerated dose (MTD) determined in a previous study, or to determine a lower MTD of the two drugs, as well as to obtain preliminary information on whether the combination of the two drugs has any effect on solid tumors in Japanese patients.
NCT01111825 ↗ Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer Completed Puma Biotechnology, Inc. Phase 1/Phase 2 2010-04-01 This is an open-label, single arm, multi-center, multi-national, adaptive design, dose-escalation Phase 1/2 study to determine the maximum tolerated dose (MTD) of temsirolimus with daily neratinib, and to determine the safety and efficacy of this combination when given to patients with advanced breast carcinoma, specifically trastuzumab-refractory HER2-amplified disease or triple-negative disease.
NCT01808573 ↗ A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting Completed Puma Biotechnology, Inc. Phase 3 2013-03-29 This is a randomized, multi-center, multinational, open-label, active-controlled, parallel design study of the combination of neratinib plus capecitabine versus the combination of lapatinib plus capecitabine in HER2+ MBC patients who have received two or more prior HER2 directed regimens in the metastatic setting.
NCT01827267 ↗ Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer Completed Puma Biotechnology, Inc. Phase 2 2013-07-01 This is a Phase 2, therapeutic-exploratory, adaptive design, open-label, multicenter, multinational study evaluating neratinib monotherapy and neratinib plus temsirolimus combination therapy in patients with non-small cell lung cancer (NSCLC) who have documented somatic HER2 mutations.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nerlynx

Condition Name

Condition Name for Nerlynx
Intervention Trials
Breast Cancer 6
HER2-positive Breast Cancer 3
ER Positive Breast Cancer 2
PR-Positive Breast Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nerlynx
Intervention Trials
Breast Neoplasms 13
Neoplasms 5
Diarrhea 3
Lung Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nerlynx

Trials by Country

Trials by Country for Nerlynx
Location Trials
United States 162
Canada 17
Spain 14
Australia 13
United Kingdom 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nerlynx
Location Trials
California 9
Massachusetts 8
Pennsylvania 7
New York 7
Florida 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nerlynx

Clinical Trial Phase

Clinical Trial Phase for Nerlynx
Clinical Trial Phase Trials
Phase 3 2
Phase 2 13
Phase 1/Phase 2 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nerlynx
Clinical Trial Phase Trials
Completed 8
Not yet recruiting 5
Recruiting 5
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nerlynx

Sponsor Name

Sponsor Name for Nerlynx
Sponsor Trials
Puma Biotechnology, Inc. 18
Dana-Farber Cancer Institute 2
National Cancer Institute (NCI) 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nerlynx
Sponsor Trials
Industry 21
Other 11
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Colorcon
Harvard Business School
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.